New Delhi, Over 200 parents from 26 states across India protested at Jantar Mantar on Wednesday with their children affected by Duchenne Muscular Dystrophy and Muscular Dystrophy , demanding urgent ...
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will ...
Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.
WVE-N531 demonstrated statistically significant improvements in muscle biopsy measures and functional measures in patients ...
Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...
Precision Biosciences Inc. recently presented a new gene-editing approach, PBGENE-DMD, which could allow life-long benefits to patients with Duchenne muscular dystrophy (DMD).
The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...
The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.
The firm will seek accelerated approval for WVE-N531 in DMD amenable to exon 53 skipping based on FDA feedback and Phase II data.
Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback